Home > ALC>

Dr. Xiaofei Wang

Duke University Medical Center, USA

Email: xiaofei.wang@duke.edu


2003 Ph.D., University of North Carolina

1999 M.Sc., University of North Carolina

1993 M.Sc., Peking University

1990 B.Sc., East China Normal University

Publications (selected)

  1. AT Schroen, GR Petroni, H Wang, M Thielen, R Gray, B Djulbegovic, XF Wang, DJ Sargent, J Benedetti, W Cronin, L Wickerham, A Denicoff, CL Slingluff (2010). Preliminary Evaluation of Factors Associated with Premature Trial Closure and Feasibility of Accrual Benchmarks in Phase III Oncology Trials. Clinical Trials7(4), 312-321; PMID: 20595245.
  2. S Dubey, P J¨anne, L Krug, XF Wang, H Pang, C Watt, J Crawford, R Kratzke, E Vokes, HL Kindler (2010). A phase II study of sorafenib in malignant mesothelioma: Results of CALGB 30307. Journal of Thoracic Oncology 5(10), 1655-1661; PMID: 20736856.
  3. J Salama, TE Stinchcombe, L Gu, XF Wang, J. Bogart, J Crawford, MA Socinski, AW Blackstock, EE Vokes (2011). Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 81(4), e269-274; PMID: 21477940.
  4. GA Masters, XF Wang, L Hodgson, E Vokes, M Green (2011). A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer 74, 258263; PMID: 21529989.
  5. R Govindan, J Bogart, T Stinchcombe, XFWang, L Hodgson, R Kratzke, J Garst, T Brotherton, E. E. Vokes for the Cancer and Leukemia Group B (2011). A Randomized Phase II Study of Pemetrexed, Carboplatin and Thoracic Radiation with or without Cetuximab in Patients with Locally Advanced Unresectable Nonsmall Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. Journal of Clinical Oncology 29(23), 3120-3125; PMID: 21747084.
  6. A Kawaguchi, GG Koch, XF Wang (2011). Stratified Multivariate Mann-Whitney Estimators for the Comparison Of Two Treatments with Randomization Based Covariance Adjustment. Statistics in Biopharmaceutical Research 3(2), 217-231.
  7. YG Wu, XF Wang (2011). Optimal Weight in Estimating the Receiver Operating Characteristic Curve Area. Biometrical Journal 53(5), 764-778; PMID: 21805488.
  8. AT Schroen, GR Petroni, H Wang, MT Thielen, DJ Sargent, J Benedetti, W Cronin, L Wickerham, XF Wang, R Gray, W Cohn, CL Slingluff Jr, B Djulbegovic (2011). Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI sponsored trials. Clinical Trials 8(5), 591-600; PMID: 21878447.
  9. MJ Edelman, XF Wang, L Hodgson, R Christenson, E Vokes, R Kratzke (2011). Serum VEGF and COX-2/5LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304.Journal of Thoracic Oncology 6(11); 1902-1906; PMID: 21964530.
  10. T Jahan, L Gu, R Kratzke, A Dudek, XF Wang, M Green, E Vokes, H Kindler for the Cancer and Leukemia Group B (2011). Vatalanib (V) in malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer Epub 2011 Dec 22; PMID: 22197613.
  11. J Chen, XF Wang, B Fan (2011). Nonparametric modeling auxiliary covariates in random coefficient models. Communications in Statistics - Simulation and Computation Epub 2011 Oct 5.
  12. MJ Edelman, L Hodgson, PY Rosenblatt, RH Christenson, E Vokes, XF Wang, R Kratzke, for the Cancer and Leukemia Group B (2012). CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304. Journal of Thoracic Oncology 7(4), 649-654.
  13. AT Schroen, GR Petroni, H Wang, MJ Thielen, R Gray, J Benedetti, XF Wang, DJ Sargent, DL Wickerham, W Cronin, B Djulbegovic, CL Slingluff Jr (2012). Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups. Clinical Cancer Research 18(1), 256-262; PMID: 21976533.